Over 40 organisations have so far signed the Oxford statement developed by IDDO and the Medicines We Can Trust campaign during the first ever-academic conference on Medicine Quality and Public Health in Oxford, 23-28 September.

If you’re in Oxford, UK between now and January 4th, 2019 visit the Radcliffe Science Library at the University of Oxford to see a new art exhibition of 14 prints illustrating the global health impact of poor quality medicines.

Researchers from IDDO and the WorldWide Antimalarial Resistance Network (WWARN) presented at the 9th European and Developing Countries Clinical Trials Partnership (EDCTP) forum held in Lisbon, Portugal from 17-21 September 2018.

Quinoline antimalarial drugs are vital tools in the fight against malaria. However, their possible effect on the heart’s rhythm raises safety concerns which may limit their use.

A WWARN Study Group recently published a large systematic literature review to understand whether undernutrition places children at higher, lower, or no differential risk for malaria. The goal was to evaluate evidence to help optimise antimalarial treatment strategies and support global health pract...

IDDO’s Ebola Data Platform, a pioneering collaboration in Ebola and emerging infections, has opened nominations for members of its Data Access Committee (DAC). Individuals with skills and expertise in clinical research, data protection and management, ethics in research and emergency public health r...

If you’re planning to be at this year’s 67th American Society of Tropical Medicine and Health Annual Meeting in New Orleans, then do come and see us. We’ll be sharing our latest results and tools at Booth 416 – so do stop by to meet the IDDO team to exchange ideas on how we might work together.

The latest results are now live on three WWARN surveyors:

ASTMH is upon us – we look forward to seeing many of our partners in the USA very soon.

Over 200 delegates traveled from more than 50 countries to attend the first ever conference on Medicine Quality and Public Health (MQPH) in Oxford from 23-28 September 2018.

Researchers from WWARN and the Infectious Diseases Data Observatory (IDDO) presented at the 9th European and Developing Countries Clinical Trials Partnership (EDCTP) forum held in Lisbon, Portugal from 17-21 September 2018.

The Infectious Diseases Data Observatory (IDDO), together with WWARN and many partners including the United States Pharmacopeia (USP), the Concept Foundation, the Mahidol Oxford Tropical Medicine Research Unit (MORU) and the Wellcome Trust are hosting the first Medicine Quality and Public Health con...

The Infectious Diseases Data Observatory (IDDO), together with many partners including the United States Pharmacopeia (USP), the Concept Foundation, the Mahidol Oxford Tropical Medicine Research Unit (MORU) and the Wellcome Trust will host the first Medicine Quality and Public Health conference at K...

We are delighted to attend the 9th EDCTP Forum in Lisbon, Portugal this week.

We are delighted to attend the 9th EDCTP Forum in Lisbon, Portugal this week.

Bangkok / Oxford, 22 August 2018 – The economic costs of antimicrobial resistance (AMR) for every course of antibiotics are considerable, and much higher than their purchase cost, say researchers.

The 2018 Global Health Journalism Fellowship will invite outstanding young journalists to participate in the first ever international conference on Medicine Quality and Public Health at the University of Oxford. Application deadline is 12 August 2018

The UK’s Department for International Development (DFID) recently announced that it will commit £9.2 million (USD 13.15 million) of funding to support a new malaria research programme lead by the Mahidol-Oxford Research Unit (MORU). The programme entitled ‘Development of Triple Artemisinin Combinati...

Have you heard of the Malaria Clinical Trials Toolkit? The ‘toolkit’ aims to improve the quality and standard of trial data by creating a step-by-step guide for researchers and clinicians on how to design, implement and analyse malaria clinical trials.

GSK and Medicines for Malaria Venture (MMV) announce FDA approval of single-dose treatment Krintafel (tafenoquine) to prevent the relapse of P. vivax malaria.